Calibr-Skaggs and Kainomyx Target Malaria Parasite's Skeleton with Gates Funding

Malaria killed an estimated 608,000 people in 2022, according to the World Health Organization - the vast majority of them children under five in sub-Saharan Africa. The disease has been treatable for decades, but resistance to artemisinin-based combination therapies, currently the frontline treatment, is spreading from Southeast Asia toward Africa. New drugs with entirely different mechanisms of action are not a future concern; they are a present-tense need.

One strategy gaining traction targets the parasite's cytoskeleton - the internal protein scaffold that Plasmodium parasites rely on to divide, move, and invade red blood cells. Disrupting that scaffold could kill the parasite without touching human cells, which use different cytoskeletal proteins. Kainomyx, a Stanford spinout founded in 2019, has spent years characterizing those parasite-specific proteins. Now the company is pairing with the Calibr-Skaggs Institute for Innovative Medicines at Scripps Research to turn that biology into drug candidates.

What the cytoskeletal target offers

Current antimalarial drugs act on a handful of established targets - the parasite's electron transport chain, its protein synthesis machinery, hemoglobin digestion. Drug-resistant Plasmodium falciparum strains have evolved workarounds for several of these. Cytoskeletal proteins have a different profile: they are structurally essential for parasite replication and diverge enough from human equivalents to offer a selectivity window.

Kainomyx brings platform capabilities for identifying, expressing, purifying, and structurally characterizing these cytoskeletal proteins. The company also develops parasite-specific biochemical and cellular assays to test whether small molecules actually disrupt the target in biologically relevant conditions.

"By targeting the parasite's cytoskeleton, we open up a new front in the battle against this disease," said Case McNamara, senior director of infectious disease at Calibr-Skaggs. "We need to stay ahead of resistance by identifying and advancing compounds with entirely new mechanisms."

What each partner brings to the pipeline

The division of labor is straightforward. Kainomyx provides cytoskeletal target materials, high-resolution structural studies, and parasite-specific assays including selectivity testing against human cell lines. Calibr-Skaggs leads medicinal chemistry and high-throughput screening, drawing on its established compound libraries and synthesis capabilities.

Both organizations will co-advance hits through the drug discovery pipeline. The collaboration includes a stated commitment to open publication and global access - a condition consistent with Gates Foundation funding priorities, which typically require that resulting medicines be affordable and available in low- and middle-income countries.

"Partnering with Calibr-Skaggs allows us to combine our strengths in target biology, biochemical and cellular assay development, and structural analysis with their world-leading medicinal chemistry and screening capabilities," said Darshan Trivedi, co-founder and president of Kainomyx.

Kainomyx founders' track record with cytoskeletal drugs

The Kainomyx team has prior precedent for turning cytoskeletal biology into approved drugs, though in a different therapeutic area. Co-founder James Spudich was also a founder of MyoKardia, whose cardiac myosin inhibitor mavacamten (Camzyos) received FDA approval in April 2022 for obstructive hypertrophic cardiomyopathy. He also co-founded Cytokinetics, whose aficamten (Myqorzo) gained FDA approval for the same indication in December 2025. Both drugs target myosin, a cytoskeletal motor protein - the same class of proteins Kainomyx is now pursuing in Plasmodium.

That lineage matters as a proof of concept for the target class, though it does not translate directly to malaria drug discovery. The parasite's cytoskeletal proteins differ structurally from cardiac myosin, and achieving the selectivity needed to kill parasites without harming patients requires its own extensive validation.

Calibr-Skaggs' nonprofit drug discovery model

Calibr-Skaggs operates as the drug discovery division of Scripps Research under a nonprofit model, meaning its pipeline advances without the commercial return-on-investment pressures that shape decisions at traditional pharmaceutical companies. The institute has advanced more than a dozen drug candidates into clinical trials, including prior antimalarial agents. Working with a Gates Foundation grant structure aligns its incentives with access and affordability rather than peak commercial pricing.

"Our mission is to translate scientific breakthroughs into real-world solutions for those most in need," said Anil Gupta, director of medicinal chemistry at Calibr-Skaggs.

Where the program stands

This collaboration is in early-stage drug discovery - identifying and optimizing small molecules that hit the cytoskeletal targets with sufficient potency and selectivity to warrant advancement. No candidates have been named, and no clinical timeline has been announced. Drug discovery campaigns of this type routinely take five to ten years before a compound enters human trials, and the majority do not succeed.

The magnitude of the public health problem - 280 million cases and more than 600,000 deaths per year, with resistance threatening current treatments - gives the scientific rationale urgency that goes beyond the commercial logic of any single company.